Idera Pharmaceuticals Revenue and Competitors

Idera Pharmaceuticals, Inc. (AMEX: IDP) is a biotechnology company engaged in the discovery and development of novel therapeutics that modulate immune responses through Toll-like receptors (TLR) for the treatment of multiple diseases. We have identified proprietary DNA-based structures that modulate TLR, which is one of the most promising new approaches in drug development. Our immune modulatory oligonucleotide (IMO™) compounds are broadly applicable to large and growing markets where significant unmet medical needs exist, including oncology, asthma/allergy, and infectious diseases. We continue to identify new drug candidates specific to various diseases, based on the differentiated biological activities of our IMO™ compounds. Our lead candidate is IMO-2055, a TLR9 agonist currently in phase 2 clinical testing for cancer. We also are collaborating with Novartis for the discovery, optimization, development, and commercialization of IMO™ drug candidates for the treatment of asthma and allergy indications.